Literature DB >> 12589097

Distribution of adenoviral vector in brain after intravenous administration.

Chanil Moon1, Cheil Moon, Wha-Sun Kang, Dae-Chul Jeong, Jong-Youl Jin.   

Abstract

The delivery of transgenes to the central nervous system (CNS) can be a valuable tool to treat CNS diseases. Various systems for the delivery to the CNS have been developed; vascular delivery of viral vectors being most recent. Here, we investigated gene transfer to the CNS by intravenous injection of recombinant adenoviral vectors, containing green fluorescence protein (GFP) as a reporter gene. Expression of GFP was first observed 6 days after the gene transfer, peaked at 14 days, and almost diminished after 28 days. The observed expression of GFP in the CNS was highly localized to hippocampal CA regions of cerebral neocortex, inferior colliculus of midbrain, and granular cell and Purkinje cell layers of cerebellum. It is concluded that intravenous delivery of adenoviral vectors can be used for gene delivery to the CNS, and hence the technique could be beneficial to gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589097      PMCID: PMC3054985          DOI: 10.3346/jkms.2003.18.1.108

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  3 in total

Review 1.  Recent advances in the pharmacology of neurological gene therapy.

Authors:  Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Curr Opin Pharmacol       Date:  2004-02       Impact factor: 5.547

2.  Inclusion of high molecular weight dextran in calcium phosphate-mediated transfection significantly improves gene transfer efficiency.

Authors:  C Wu; Y Lu
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2007-05-15       Impact factor: 1.770

3.  Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.

Authors:  Diego Montano
Journal:  Front Public Health       Date:  2022-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.